Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The modes of action and clinical implications of several of the newest classes of antidiabetic drugs used as monotherapy and as add-on therapy have been extensively reviewed in recent publications.1 2 Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg, empagliflozin) belong to one such novel class and act via interference with proximal renal tubular reabsorption of glucose; about 90% of such reabsorption depends on this cotransporter. They therefore reduce blood glucose concentrations, promote weight reduction and lower blood pressure through glycosuria and osmotic diuresis. Moreover, since their activity is independent of insulin, they are efficacious even in the presence of pancreatic beta cell failure, which is in marked contrast to many other antidiabetic drugs. Furthermore, polyuria and polydipsia are uncommon. Gliptins (eg, saxagliptin) form another new class of oral antidiabetic agents that reduce glucagon secretion but promote insulin release by interfering with the degradation of incretins (intestinal hormones produced in response to ingested meals), and are generally well tolerated. Glucagon-like-peptide 1 (GLP1) receptor agonists (eg, exenatide) are incretin mimetics that constitute yet another class of new antidiabetics and, together with SGLT2 inhibitors, are the only antidiabetic drugs that have a favourable weight loss effect. Subcutaneous administration and gastrointestinal side effects are distinct disadvantages. In contrast to many other antidiabetic agents, treatments with drugs in these three classes and metformin confer a lower risk of hypoglycaemia.
Type 2 diabetes mellitus (T2DM) is more than just a disorder of glucose metabolism. Patients with T2DM die prematurely because of cardiovascular disease and renal failure. The goal of drug treatment of diabetes should therefore be more than just controlling the blood glucose. In the aftermath of the rosiglitazone controversy,3 …
Contributors CRK: Acquired relevant data, undertook its analysis and interpretation of findings; conceived the message for the editorial and produced the first draft; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.
KCBT: Provided necessary reference material; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.
BMYC: Contributed to the conception of the message; drafted sections of the manuscript and reviewed data interpretation; critically revised the manuscript and approved the final version; agrees to be accountable for the contents, including its integrity and accuracy.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.